Genvoya, used as Genvoya fumarate (TAF ), is a nucleotide reverse transcriptase inhibitor and a novel prodrug of tenofovir. It is under development by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (Viread), TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Genvoya was approved in the U.S. in November 2015 for use in combination with elvitegravir, cobicistat, and emtricitabine for the treatment of HIV .
Strength: Cobicistat 150 Mg / Elvitegravir 150 Mg / Emtricit
Pill Imprint: GSI 510
View Images & Details